Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PGEN | Common Stock | Options Exercise | +18.9K | +6.16% | 326K | Jan 4, 2022 | Direct | F1 | ||
transaction | PGEN | Common Stock | Sale | -$35K | -9.74K | -2.99% | $3.59 | 316K | Jan 5, 2022 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PGEN | Restricted Stock Units | Options Exercise | $0 | -18.9K | -50% | $0.00 | 18.9K | Jan 4, 2022 | Common Stock | 18.9K | Direct | F1, F3 |
Id | Content |
---|---|
F1 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. |
F2 | This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs. |
F3 | The RSUs were granted on January 4, 2019 and the remaining RSUs vest on January 4, 2023. |